Dysexecutive versus amnestic alzheimer disease subgroups: Analysis of demographic, genetic, and vascular factors

Alzheimer Disease and Associated Disorders

Volumn 27, Issue 3, 2013, Pages 218-225

  Mez, Jesse ^a,b,c   Cosentino, Stephanie ^a,b,c   Brickman, Adam M ^a,b,c   Huey, Edward D ^a,b,c   Manly, Jennifer J ^a,b,c   Mayeux, Richard ^a,b,c,d  

^a Vagelos College of Physicians and Surgeons   (United States)

^b NONE   (United States)

^c Department of Medicine   (United States)

^d New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Alzheimer disease; APOE; executive function; memory; mild cognitive impairment; vascular risk factors

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; ETHNIC GROUP; EXECUTIVE FUNCTION; FEMALE; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; COMPLICATION; GENETICS; NEUROPSYCHOLOGICAL TEST; PHENOTYPE; VASCULAR DISEASES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; FEMALE; GENOTYPE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PHENOTYPE; VASCULAR DISEASES;

EID: 84878660686     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e31826a94bd     Document Type: Article

References (33)

1. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDSADRDA criteria. Lancet Neurol. 2007;6:734-746.
2. Binetti G, Magni E, Padovani A, et al. Executive dysfunction in early Alzheimer's disease. J Neurol Neurosurg Psychiatr. 1996;60:91-93.
3. Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. Brain. 2007;130(pt 10):2636-2645.
4. Stuss DT, Alexander MP. Is there a dysexecutive syndrome? Philos Trans R Soc Lond, B Biol Sci. 2007;362:901-915.
5. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
6. Dickerson BC, Wolk DA. Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. J Neurol Neurosurg Psychiatr. 2011;82:45-51.
7. Snowden JS, Stopford CL, Julien CL, et al. Cognitive phenotypes in Alzheimer's disease and genetic risk. Cortex. 2007;43:835-845.
8. Johnson JK, Head E, Kim R, et al. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol. 1999;56:1233-1239.
9. Johnson JK, Vogt BA, Kim R, et al. Isolated executive impairment and associated frontal neuropathology. Dement Geriatr Cogn Disord. 2004;17:360-367.
10. Bracco L, Bessi V, Piccini C, et al. Metabolic correlates of executive dysfunction. Different patterns in mild and very mild Alzheimer's disease. J Neurol. 2007;254:1052-1065.
11. Pa J, Boxer A, Chao LL, et al. Clinical-neuroimaging characteristics of dysexecutive mild cognitive impairment. Ann Neurol. 2009;65:414-423.
12. Chao LL, Pa J, Duarte A, et al. Patterns of cerebral hypoperfusion in amnestic and dysexecutive MCI. Alzheimer Dis Assoc Disord. 2009;23:245-252.
13. Chang Y-L, Jacobson MW, Fennema-Notestine C, et al. Level of executive function influences verbal memory in amnestic mild cognitive impairment and predicts prefrontal and posterior cingulate thickness. Cereb Cortex. 2010;20:1305-1313.
14. Desmond DW, Tatemichi TK, Paik M, et al. Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort. Arch Neurol. 1993;50:162-166.
15. Robbins MA, Elias MF, Elias PK, et al. Blood pressure and cognitive function in an African-American and a Caucasian-American sample: the Maine-Syracuse Study. Psychosom Med. 2005;67:707-714.
16. Goldstein FC, Ashley AV, Endeshaw Y, et al. Effects of hypertension and hypercholesterolemia on cognitive functioning in patients with Alzheimer's disease. Alzheimer Dis Assoc Disord. 2008;22:336-342.
17. Lamar M, Libon DJ, Ashley AV, et al. The impact of vascular comorbidities on qualitative error analysis of executive impairment in Alzheimer's disease. J Int Neuropsychol Soc. 2010;16:77-83.
18. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20:210-216.
19. Fischer P, Jungwirth S, Zehetmayer S, et al. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology. 2007;68:288-291.
20. Weintraub S, Salmon D, Mercaldo N, et al. The Alzheimer's Disease Centers? Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord. 2009;23: 91-101.
21. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:1095-1097.
22. Hayden KM, Jones RN, Zimmer C, et al. Factor structure of the National Alzheimer's Coordinating Centers uniform dataset neuropsychological battery: an evaluation of invariance between and within groups over time. Alzheimer Dis Assoc Disord. 2011;25:128-137.
23. Anon. SPSS for Windows. Chicago: SPSS Inc.; 2010.
24. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349-1356.
25. Yaffe K, Petersen RC, Lindquist K, et al. Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord. 2006;22:312-319.
26. Bondi MW, Jak AJ, Delano-Wood L, et al. Neuropsychological contributions to the early identification of Alzheimer's disease. Neuropsychol Rev. 2008;18:73-90.
27. Schwartz BS, Glass TA, Bolla KI, et al. Disparities in cognitive functioning by race/ethnicity in the Baltimore Memory Study. Environ Health Perspect. 2004;112:314-320.
28. Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004; 19:203-214.
29. Koedam ELGE, Lauffer V, van der Vlies AE, et al. Earlyversus late-onset Alzheimer's disease: more than age alone. J Alzheimers Dis. 2010;19:1401-1408.
30. Geroldi C, Pihlajama? ki M, Laakso MP, et al. APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology. 1999;53:1825-1832.
31. Wolk DA, Dickerson BC. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci USA. 2010;107:10256-10261.
32. Pievani M, Rasser PE, Galluzzi S, et al. Mapping the effect of APOE epsilon4 on gray matter loss in Alzheimer's disease in vivo. Neuroimage. 2009;45:1090-1098.
33. Reitz C, Patel B, Tang M-X, et al. Relation between vascular risk factors and neuropsychological test performance among elderly persons with Alzheimer's disease. J Neurol Sci. 2007; 257:194-201.